[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 276
56. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY: Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg; 2008 Dec;12(12):2078-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma.
  • INTRODUCTION: Pancreatic acinar cell carcinoma (ACC) is a rare tumor with poorly defined prognosis.
  • OBJECTIVE: Our objective was to compare a large population of patients with ACC to pancreatic ductal cell adenocarcinoma (DCC) in order to determine distinguishing characteristics and to assess survival.
  • RESULTS: Median tumor size was 6.9 cm (vs. 4.6 cm DCC); 32.1% had nodal metastases (vs. 48.0% DCC); and 47% had high-grade tumors (vs. 37.3% DCC).
  • Patients with ACC were more likely to be male, white, and have larger tumor size, no nodal involvement, or pancreatic tail tumors.
  • On multivariable analysis, age < 65, well-differentiated tumors, and negative resection margins were independent prognostic factors for ACC.
  • [MeSH-major] Carcinoma, Acinar Cell / epidemiology. Carcinoma, Acinar Cell / surgery. Pancreatic Neoplasms / epidemiology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Chi-Square Distribution. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Pancreatectomy. Prognosis. ROC Curve. Regression Analysis. Statistics, Nonparametric. Survival Rate. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Ann Surg Oncol. 2008 Mar;15(3):683-90 [18183467.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] J Surg Oncol. 2004 Jan;85(1):1-3 [14696080.001]
  • [Cites] J Gastrointest Surg. 2009 Aug;13(8):1495-502 [19495891.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • (PMID = 18836784.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Wahid A, Ahmad S, Sajjad M: Pattern of carcinoma of oral cavity reporting at dental department of Ayub medical college. J Ayub Med Coll Abbottabad; 2005 Jan-Mar;17(1):65-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of carcinoma of oral cavity reporting at dental department of Ayub medical college.
  • BACKGROUND: Carcinoma of oral cavity is amongst the first ten commonest malignancies in Pakistan.
  • METHODDS: This clinicopathological study consists of cases of carcinoma of oral cavity presenting to dentistry department of Ayub Medical College Abbottabad during 1993-2003.
  • RESULTS: There were 50 carcinoma cases in the study, including 30 (60%) males and 20 (40%) females.
  • Among these, 47 (94%,) were diagnosed as squamous cell carcinomas, that consisted 30 (63.82 %) males and 17 (36.17%) females.
  • The other 6 % lesions were histologically diagnosed as malignant melanoma, adenocarcinoma and acinar cell carcinoma.
  • The age of squamous cell carcinoma cases was 41-71 years.
  • The maximum number of squamous cell carcinomas (34%) effected buccal mucosa.
  • CONCLUSION: The results of this study are comparable with other such studies done in Pakistan and else where in the world showing commonality of factors associated with the development of the disease in this region of the country, which necessitates a detailed prospective study.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929532.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


58. Buchner A, Merrell PW, Carpenter WM: Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med; 2007 Apr;36(4):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world.
  • BACKGROUND: The relative frequency of individual intra-oral minor salivary gland tumors (IMSGT) is not well documented in the literature.
  • Tumors were classified according to the 2005 WHO classification of salivary gland tumors.
  • Of the 380 tumors, 224 (59%) were benign and 156 (41%) were malignant.
  • Of the benign tumors, pleomorphic adenoma (PA) was the most common (39.2%), followed by cystadenoma (6.3%), canalicular adenoma (6.1%), ductal papillomas (4.4%), basal cell adenoma (1.6%), and myoepithelioma (1.3%).
  • Of the malignant tumors, mucoepidermoid carcinoma was the most common (21.8%), followed by polymorphous low-grade adenocarcinoma (7.1%), adenoid cystic carcinoma (6.3%), adenocarcinoma, not otherwise specified (NOS; 2.1%), acinic cell carcinoma (1.6%), clear cell carcinoma, NOS (1.0%), and carcinoma ex PA (0.5%).
  • CONCLUSIONS: Studies related to the relative frequency of individual IMSGTs from different parts of the world are difficult to compare because many studies are outdated, the number of cases is small, the list of tumors is limited, and new entities are not included.
  • To determine the true relative frequency, more studies should be conducted, on a large number of cases from one source, by experienced pathologists in the field of salivary gland tumors.
  • [MeSH-minor] Adenoma, Pleomorphic / epidemiology. Adenoma, Pleomorphic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Mucoepidermoid / pathology. Child. Cystadenoma / epidemiology. Cystadenoma / pathology. Female. Humans. Male. Middle Aged. Prevalence

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391298.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


59. Suzuki M, Sakurai H, Seno S, Hoshi J, Ogawa T, Arikata M, Tojima I, Kitanishi T, Tanaka H, Shimizu T: [Endoscopic resection of benign and malignant tumors in the nasal cavity and paranasal sinus]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Jul;108(7):724-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic resection of benign and malignant tumors in the nasal cavity and paranasal sinus].
  • Endoscopic resection of nasal and paranasal sinus tumors is more aesthetic and less invasive than conventional resection, such as Luc's operation and lateral rhinotomy.
  • We clarified the effect of radical endoscopic tumor excision and the control of local bleeding hazardous in endoscopic surgery.
  • Subjects were patients with benign lesions in the nasal cavity, medial wall of the maxillary sinus, ethmoid sinus, and/or sphenoid sinus without concurrent malignant lesions.
  • Although patients selection for malignant tumor excision was based on (1) possible en bloc resection, (2) low-grade malignant tumors, and (3) tumors in the nasal cavity and adjoining paranasal sinus, the final decision was made individual.
  • Subjects were 23 patients with benign tumor (10 inverted papilloma, 9 hemangioma, 2 juvenile angiofibroma, and 2 other tumors) and 4 with malignant tumor (olfactory neuroblastoma, acinic cell carcinoma, squamous cell carcinoma, and chondroid chordoma) in the nasal and paranasal sinus.
  • The tumor was resected en bloc except for patients with inverted papilloma (2 cases) and chondroid chordoma.
  • Recurrence in benign tumors was zero during a mean observation of 21 months.
  • Endoscopic removal of malignant lesions remains controversial because of the small number of patients and short postoperative observation.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107047.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Hsu MY, Pan KT, Chu SY, Hung CF, Wu RC, Tseng JH: CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations. Clin Radiol; 2010 Mar;65(3):223-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT and MRI features of acinar cell carcinoma of the pancreas with pathological correlations.
  • AIM: To document the computed tomography (CT) and magnetic resonance imaging (MRI) features of acinar cell carcinoma of the pancreas and to correlate them with pathological findings to determine the unique imaging manifestations of this rare subtype tumour of the pancreas.
  • MATERIALS AND METHODS: From January 1986 to August 2008, six patients (five men and one woman, mean age 61.3 years) with histologically proven acinar cell carcinoma of the pancreas underwent CT (n=6) and MRI (n=4) examinations.
  • CONCLUSION: Acinar cell carcinoma of the pancreas has distinct imaging features, and both CT and MRI are useful and complementary imaging methods.
  • [MeSH-major] Carcinoma, Acinar Cell. Magnetic Resonance Imaging. Pancreatic Neoplasms. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pancreas, Exocrine. Retrospective Studies. Sex Distribution. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20152279.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


61. Kataoka Y, Nio Y, Yano S, Koike M, Hashimoto K, Itakura M, Itagaki T, Nishi T, Endo S, Higami T: [Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin]. Gan To Kagaku Ryoho; 2006 Apr;33(4):525-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin].
  • Pancreatic acinar cell carcinomas are rare, and little is reported on their chemotherapy.
  • We report a 49-year old male patient with pancreatic acinar cell carcinoma and multiple liver metastases, which responded to oral TS-1 and hepatic arterial infusion of cisplatin.
  • The patient underwent a partial hepatectomy, MCT abrasions and excision of the pancreatic tumor.
  • Postoperative pathological studies revealed metastases of acinar cell carcinoma to the liver and lymph nodes; the primary lesion was undetermined.
  • Metastatic tumors completely disappeared, and serum lipase decreased to normal levels.
  • Abdominal CT one year after surgery revealed a pancreatic body tumor, which was surgically removed.
  • Pathological studies showed primary pancreatic acinar cell carcinoma, while previous metastases remained under control.
  • To summarize, TS-1 and cisplatin can be effective treatments for pancreatic acinar cell carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Acinar Cell / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612167.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Du YC, Klimstra DS, Varmus H: Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS One; 2009 Sep 07;4(9):e6932
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors.
  • It is unclear whether the cellular origin of various forms of pancreatic cancer involves transformation or transdifferentiation of different target cells or whether tumors arise from common precursors, with tumor types determined by the specific genetic alterations.
  • Previous studies suggested that pancreatic ductal carcinomas might be induced by polyoma middle T antigen (PyMT) expressed in non-ductal cells.
  • To ask whether PyMT transforms and transdifferentiates endocrine cells toward exocrine tumor phenotypes, we generated transgenic mice that carry tetracycline-inducible PyMT and a linked luciferase reporter.
  • Induction of PyMT in beta cells causes beta-cell hyperplastic lesions that do not progress to malignant neoplasms.
  • When PyMT is de-induced, beta cell proliferation and growth cease; however, regression does not occur, suggesting that continued production of PyMT is not required to maintain the viable expanded beta cell population.
  • In contrast, induction of PyMT in early pancreatic progenitor cells under the control of Pdx1 produces acinar cell carcinomas and beta-cell hyperplasia.
  • The survival of acinar tumor cells is dependent on continued expression of PyMT.
  • Our findings indicate that PyMT can induce exocrine tumors from pancreatic progenitor cells, but cells in the beta cell lineage are not transdifferentiated toward exocrine cell types by PyMT; instead, they undergo oncogene-dependent hyperplastic growth, but do not require PyMT for survival.

  • Hazardous Substances Data Bank. TETRACYCLINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Mol Biol Rev. 2001 Jun;65(2):288-318 ; second and third pages, table of contents [11381103.001]
  • [Cites] Nature. 2008 Oct 2;455(7213):627-32 [18754011.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1133-7 [11590437.001]
  • [Cites] Cell Transplant. 2001;10(7):645-50 [11714200.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1631-8 [11733558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3818-23 [11904435.001]
  • [Cites] Cell. 2002 May 3;109(3):321-34 [12015982.001]
  • [Cites] Nat Rev Genet. 2002 Jul;3(7):524-32 [12094230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12236-41 [12221286.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):951-6 [12459733.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):488-501 [12600942.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3127-38 [14681205.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Nature. 2004 May 6;429(6987):41-6 [15129273.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1128-32 [1371010.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):671-84 [7521578.001]
  • [Cites] Nature. 1994 Oct 13;371(6498):606-9 [7935793.001]
  • [Cites] J Clin Invest. 1994 Dec;94(6):2421-5 [7989599.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2105-16 [8804306.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):6002-13 [9315659.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1228-37 [15684377.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2772-81 [16537919.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4511-8 [16738317.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:1-9 [16869733.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):961-70 [17404619.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S94-112 [17486055.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080 [18451130.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1841-4 [18755941.001]
  • [Cites] Diabetes. 2001 Oct;50(10):2260-7 [11574407.001]
  • (PMID = 19812721.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA105492; United States / NCI NIH HHS / CA / P30 CA08748; United States / NCI NIH HHS / CA / P01 CA94060; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P30-CA 08748; United States / NCI NIH HHS / CA / P01 CA094060; United States / NCI NIH HHS / CA / R24 CA83084; United States / NCI NIH HHS / CA / 5U01CA105492; United States / NCI NIH HHS / CA / R24 CA083084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; EC 1.13.12.- / Luciferases; F8VB5M810T / Tetracycline
  • [Other-IDs] NLM/ PMC2758666
  •  go-up   go-down


63. Ikeda S, Fujimori M, Shibata S, Okajima M, Ishizaki Y, Kurihara T, Miyata Y, Iseki M, Shimizu Y, Tokumoto N, Ozaki S, Asahara T: Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer; 2006;6:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer.
  • However, often, the discriminating diagnosis of primary lung acinar adenocarcinoma and lung metastasis of colorectal cancer based on morphological and pathological findings is difficult.
  • The purpose of this study was to evaluate the clinical usefulness of immunohistochemistry of beta-catenin, cytokeratin (CK) 7, and CK20 for the discriminating diagnosis of lung cancer.
  • METHODS: We performed immunohistochemistry of beta-catenin, CK7, and CK20 in 19 lung metastasis of colorectal cancer samples, 10 corresponding primary colorectal cancer samples and 11 primary lung acinar adenocarcinoma samples and compared the levels of accuracy of the discriminating diagnosis by using antibodies against these antigens.
  • RESULTS: Positive staining of beta-catenin was observed in all the lung metastasis of colorectal cancer samples as well as in the primary colorectal cancer samples but in none of the primary lung acinar adenocarcinoma samples.
  • Positive staining of CK7 was observed in 90.9% of the primary lung acinar adenocarcinoma samples and in 5.3% of the lung metastasis of colorectal cancer samples, but in none of the primary colorectal cancer samples.
  • Positive staining of CK20 was observed in all the primary colorectal cancer samples and in 84.2% of the lung metastasis of colorectal cancer samples, but in none of the primary lung acinar adenocarcinoma samples.
  • CONCLUSION: Combined immunohistochemistry of beta-catenin, CK7, and CK20 is useful for making a discriminating diagnosis between lung metastasis of colorectal cancer and primary lung acinar adenocarcinoma.
  • This method will enable accurate diagnosis of a lung tumor and will be useful for selecting appropriate therapeutic strategies, including chemotherapeutic agents and operation methods.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Gene Expression Profiling. Humans. Immunohistochemistry. Keratin-20. Keratin-7. Keratins / analysis. Retrospective Studies. Sensitivity and Specificity. beta Catenin / analysis


6
Advertisement
4. Hirota SK, Modolo F, Portela de Albuquerque MA, Lehn CN, Sugaya NN, Machado de Sousa SO, Paraiso Cavalcanti MG: Recurring acinic cell carcinoma of the buccal mucosa: a case report. Quintessence Int; 2007 Apr;38(4):289-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurring acinic cell carcinoma of the buccal mucosa: a case report.
  • A case of acinic cell adenocarcinoma of the left facial area of 10-years' duration in a 29-year-old man is presented.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Neoplasm Recurrence, Local. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Keratin-7 / analysis. Keratin-8 / analysis. Ki-67 Antigen / analysis. Male. Mouth Mucosa / pathology. Vimentin / analysis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432783.001).
  • [ISSN] 0033-6572
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Vimentin
  •  go-up   go-down


65. Mocan S, Stolnicu S, Rădulescu D, Petrovan C: [Acinic cell adenocarcinoma of the lip]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell adenocarcinoma of the lip].
  • [Transliterated title] Adenocarcinom cu celule acinare cu localizare la nivelul buzei. Prezentare de caz.
  • The variable histological appearance of acinic cell carcinoma coupled with its uncommon occurrence account for considerable diagnostic difficulties.
  • Different cellular features were recognised in the tumour, with the presence of both serous and mucous acinar differentiation.
  • Acinic cell adenocarcinoma is a malignant epithelial neoplasm in which the neoplastic cells demonstrate not only serous acinar differentiation.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607848.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


66. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • The HER-2/neu (c-erbB-2) gene has been reportedly overexpressed in adenoid cystic carcinomas in other organs, but its status in prostatic ACBCC was uncertain.
  • Ten acinar adenocarcinomas of varying grades were also immunostained as controls.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism


67. Nagliati M, Bolner A, Vanoni V, Tomio L, Lay G, Murtas R, Deidda MA, Madeddu A, Delmastro E, Verna R, Gabriele P, Amichetti M: Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori; 2009 Jul-Aug;95(4):442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study.
  • The low incidence and heterogeneity of primary parotid carcinomas makes their outcome difficult to evaluate.
  • The present study reviews the experience of three Italian institutions in the treatment of primary parotid carcinomas in order to describe the clinicopathological presentation and treatment options with emphasis on radiotherapy and to analyze the factors influencing survival.
  • The influence of selected factors on 10-year disease-specific survival was analyzed.
  • The most frequent histologies were adenoid cystic carcinoma (n = 16), mucoepidermoid carcinoma (n = 15), and acinic cell carcinoma (n = 15).
  • Actuarial 10-year disease-specific survival was 71% and actuarial 10-year local control 82%.
  • Our study confirms the results of the literature with surgery and adjunctive radiotherapy in patients with advanced-stage disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856654.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


68. Varsegi MF, Ravis SM, Hattab EM, Henley JD, Billings SD: Widespread cutaneous metastases from acinic cell carcinoma 20 years after primary presentation. J Cutan Pathol; 2008 Jun;35(6):591-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Widespread cutaneous metastases from acinic cell carcinoma 20 years after primary presentation.
  • Acinic cell carcinoma is a rare, low-grade malignant salivary gland neoplasm.
  • We present a case of widespread cutaneous metastasis from acinic cell carcinoma arising in a 59-year-old woman with a history of acinic cell carcinoma of the parotid gland 20 years prior to her cutaneous disease.
  • To our knowledge, is the first report of widespread cutaneous metastasis from acinic cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Parotid Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cell Nucleus / pathology. Cytoplasmic Granules / pathology. Female. Humans. Middle Aged. Periodic Acid-Schiff Reaction

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261112.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Díaz Sánchez A, Ponferrada Díaz A, Senosiain Labiano M, Huerta Madrigal A: [Upper digestive hemorrhage as the first manifestation of acinar cell carcinoma of the pancreas]. Gastroenterol Hepatol; 2006 Jun-Jul;29(6):380
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upper digestive hemorrhage as the first manifestation of acinar cell carcinoma of the pancreas].
  • [Transliterated title] Hemorragia digestiva alta como presentación de un carcinoma acinar pancreático.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Gastrointestinal Hemorrhage / etiology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Duodenal Neoplasms / diagnosis. Female. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790192.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


70. Alphs HH, Eisele DW, Westra WH: The role of fine needle aspiration in the evaluation of parotid masses. Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration is notoriously unreliable in recognizing the malignant nature of the parotid carcinoma, providing its precise classification, and establishing its grade.
  • A few malignant neoplasms are particularly prone to diagnostic error.
  • Acinic cell carcinoma is frequently interpreted as benign or even nonneoplastic; and low-grade lymphomas are often discounted as inflammatory processes.
  • [MeSH-minor] Diagnosis, Differential. Frozen Sections. Humans. Parotid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552260.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


71. Martínez-Cornelio A, González-Pérez J, Tabares-García Fde J, Ramos-Salgado F, Alvarado-Cabrero I, Hernández-Toriz N: [Androgen-deprivation therapy in the management of neuroendocrine prostate cancer]. Cir Cir; 2009 Jul-Aug;77(4):293-9; 273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prostatic neuroendocrine carcinomas comprise <1% of all prostate neoplasms, and approximately 200 cases have been reported in the literature.
  • We undertook this study to describe the experience in the management of prostatic neuroendocrine carcinoma with androgen-deprivation therapy (ADT).
  • Patients were selected by anatomopathological diagnostic study of neuroendocrine carcinoma including pure and mixed variants.
  • Symptoms at diagnosis were associated with metastasis to other organs, one with bone metastasis, and presenting pain in 100% of the cases.
  • In six (60%) patients mixed variant was documented (acinar adenocarcinoma and neuroendocrine carcinoma) with a median survival of 11.6 months.
  • In four patients (40%), pure neuroendocrine carcinoma was documented with a median survival of 7 months.
  • CONCLUSIONS: Prostatic neuroendocrine carcinoma is uncommon, aggressive and represents a prostatic neoplasia without PSA expression.
  • In advanced disease, very low response is reached with ADT.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Prostatic Neoplasms / drug therapy


72. Hashimoto M, Miki K, Kokudo N, Beck Y, Makuuchi M: A long-term survivor of metastatic acinar cell carcinoma. Pancreas; 2007 Mar;34(2):271-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of metastatic acinar cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312470.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


73. Sabbagh C, Fuks D, Chatelain D, Flamant M, Delcenserie R, Yzet T, Regimbeau JM: [Acinar cell carcinoma of the pancreas: a rare tumor with particular clinical and paraclinical presentation]. Rev Med Interne; 2008 Dec;29(12):1046-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinar cell carcinoma of the pancreas: a rare tumor with particular clinical and paraclinical presentation].
  • [Transliterated title] Carcinome à cellules acineuses du pancréas : une tumeur rare avec des caractéristiques cliniques et paracliniques particulières.
  • Acinar cell carcinoma of the pancreas is a rare tumour with specific clinical and paraclinical presentation.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433943.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


74. Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O: Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol; 2008 Jun;44(6):563-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors.
  • Maspin, a 42kDa protein, belongs to the serine protease inhibitor (serpin) family and is suggested to have inhibitory effects on tumor-induced angiogenesis, tumor cell motility, invasion and metastasis and influences prognosis of tumor patients.
  • High proportions of Maspin expression were observed in adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas ex pleomorphic adenoma, low proportions were seen in salivary duct carcinomas.
  • Acinic cell carcinomas did not show any Maspin expression.
  • Analysis of the prognostic impact of Maspin expression was restricted to salivary gland carcinoma types of intermediate malignancy grade (adenoid cystic carcinoma, mucoepidermoid carcinoma and carcinoma ex pleomorphic adenoma).
  • For these tumors, univariate analyses revealed that T-stage (p=0.025), age70 (p=0.0065), loss of Maspin (p=0.0016) and presence of residual tumor (p<0.001) correlated with poor prognosis.
  • Moreover, negative Maspin staining was associated with lymph node metastasis and residual tumor.
  • According to these findings, Maspin might be useful as a new prognostic marker in adenoid cystic carcinoma and in salivary gland carcinomas with intermediate grade of malignancy where grading systems are still under debate.
  • [MeSH-major] Carcinoma, Mucoepidermoid / metabolism. Salivary Gland Neoplasms / metabolism. Serpins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / mortality. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prognosis. Serine Proteinase Inhibitors / pharmacology. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936671.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


75. Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F, Ussmueller JO, Adam G, Jaehne M: Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? AJNR Am J Neuroradiol; 2009 Mar;30(3):591-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible?
  • BACKGROUND AND PURPOSE: Our aim was to determine the value of echo-planar diffusion-weighted MR imaging (epiDWI) in differentiating various types of primary parotid gland tumors.
  • MATERIALS AND METHODS: One hundred forty-nine consecutive patients with suspected tumors of the parotid gland were examined with an epiDWI sequence by using a 1.5T unit.
  • Histologic diagnosis was obtained in every patient.
  • RESULTS: In 136 patients, a primary parotid gland tumor was confirmed by histology.
  • ADC values of Warthin tumors were different from those of myoepithelial adenomas, lipomas, and salivary duct carcinomas (P < .001, 0.013, and .037, respectively).
  • Mucoepidermoid carcinomas, acinic cell carcinomas, and basal cell adenocarcinomas were not differentiable from Warthin tumors (P = .094, .396, and .604, respectively).
  • Due to an overlap not only within the group of benign and malignant lesions but also between groups, diagnoses should not be addressed on the basis of ADC values solely.
  • Therefore, further studies combining DWI, morphologic criteria, and probably other MR imaging techniques seem warranted.
  • [MeSH-minor] Adenolymphoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Female. Humans. Lipoma / pathology. Male. Middle Aged. Prospective Studies. Salivary Gland Neoplasms / pathology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131405.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH: Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol; 2005 Jun;18(6):752-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
  • Solid pseudopapillary tumor, pancreatoblastoma, undifferentiated carcinoma with osteoclastic-like giant cells, and acinar cell carcinomas are rare pancreatic nonductal neoplasms.
  • Compared to the significant advances in our understanding of the pathogenesis of pancreatic ductal adenocarcinomas in the last decades, the molecular mechanisms underlying pancreatic nonductal neoplasms are poorly understood.
  • In order to elucidate their molecular pathogenesis, we constructed tissue microarrays to study the expression of some novel pancreatic ductal adenocarcinoma-associated tumor markers in these nonductal pancreatic neoplasms.
  • We analyzed nine markers including tumor suppressor gene (14-3-3 sigma), proliferation marker (topoisomerase II alpha), epithelial markers (prostate stem cell antigen, mesothelin and cytokeratin 19), stromal markers (fascin, hsp47 and fibronectin), and gamma-synuclein whose function is not delineated.
  • In addition, we included tumor suppressor gene DPC4 and oncogene Beta-catenin to further confirm their expression in pancreatic nonductal tumors.
  • Our results showed that in contrast to pancreatic ductal adenocarcinomas that show loss of Dpc4 protein in 55% of cases, loss of Dpc4 expression is absent in pancreatic nonductal neoplasms.
  • Expression of 14-3-3 sigma is frequently seen in both pancreatic nonductal neoplasms (25-100%) and ductal adenocarcinomas (89%).
  • Aberrant nuclear expression of beta-catenin is common in pancreatic nonductal neoplasms, specifically in solid pseudopapillary tumors (88%) and pancreatoblastomas (100%) but is rarely seen in pancreatic ductal adenocarcinomas (<5%).
  • Expression of topoisomerase II alpha is not seen in solid pseudopapillary tumors and undifferentiated carcinomas with osteoclastic-like giant cells but is focally seen in pancreatoblastomas (50%) and acinar cell carcinomas (85%).
  • Expression of PSCA and mesothelin was observed in pancreatic nonductal neoplasms but their expression was seen less frequently (0-50%) and weaker than that in pancreatic ductal adenocarcinomas (60-100%).
  • CK19, a marker of pancreatic ductal adenocarcinomas, is not expressed in pancreatic nonductal neoplasms.
  • Our findings indicate pancreatic nonductal neoplasms have distinctive patterns of protein expression relative to pancreatic ductal adenocarcinomas and suggest that pancreatic nonductal neoplasms have different genetic pathways from the more common pancreatic ductal adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] 14-3-3 Proteins. Antigens, Neoplasm. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carrier Proteins / analysis. Cytoskeletal Proteins / analysis. DNA-Binding Proteins / analysis. Exonucleases / analysis. Exoribonucleases. Fibronectins / analysis. GPI-Linked Proteins. HSP47 Heat-Shock Proteins. Heat-Shock Proteins / analysis. Humans. Immunohistochemistry. Keratins / analysis. Membrane Glycoproteins / analysis. Microfilament Proteins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis. Serpins / analysis. Smad4 Protein. Synucleins. Trans-Activators / analysis. beta Catenin. gamma-Synuclein

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696124.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Fibronectins; 0 / GPI-Linked Proteins; 0 / HSP47 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Glycoproteins; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / PSCA protein, human; 0 / SERPINH1 protein, human; 0 / SMAD4 protein, human; 0 / Serpins; 0 / Smad4 Protein; 0 / Synucleins; 0 / Trans-Activators; 0 / beta Catenin; 0 / gamma-Synuclein; 0 / mesothelin; 146808-54-0 / fascin; 68238-35-7 / Keratins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


77. Peng HQ, Darwin P, Papadimitriou JC, Drachenberg CB: Liver metastases of pancreatic acinar cell carcinoma with marked nuclear atypia and pleomorphism diagnosed by EUS FNA cytology: a case report with emphasis on FNA cytological findings. Cytojournal; 2006;3:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastases of pancreatic acinar cell carcinoma with marked nuclear atypia and pleomorphism diagnosed by EUS FNA cytology: a case report with emphasis on FNA cytological findings.
  • BACKGROUND: Acinar cell carcinoma of the pancreas is a rare neoplasm.
  • Although this tumor has been well characterized histologically, the morphological patterns in Fine Needle Aspiration Cytology have not been well defined.
  • Unlike ductal adenocarcinomas, endocrine tumors, and solid pseudopapillary tumors of the pancreas with their characteristic FNA cytological features, acinar cell carcinomas pose a particular diagnostic challenge by sharing many cytomorphologic features with endocrine tumors of the pancreas.
  • FNA cytology revealed abundant, loosely cohesive clusters of malignant epithelial cells with vaguely acinar and trabecular formations.
  • Scattered, strikingly large tumor cells with giant nuclei, prominent mitoses and associated necrosis were evident.
  • A pancreatic endocrine tumor was suspected initially, but acinar cell carcinoma of the pancreas was confirmed by immunohistochemistry, cytochemical and ultrastructural studies.
  • CONCLUSION: We describe a case of pancreatic acinar cell carcinoma with unusual cytomorphologic features mimicking an endocrine tumor of pancreas, encountered in endoscopic ultrasound-guided fine needle aspiration of a metastatic liver mass and discuss the diagnostic approach for this unusual pancreatic tumor in fine needle aspiration cytology.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):100-5 [16007666.001]
  • [Cites] Endoscopy. 2003 Sep;35(9):743-9 [12929021.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Gastroenterol. 2005 Sep;40(9):907-11 [16211348.001]
  • [Cites] Cytopathology. 2006 Feb;17(1):34-41 [16417563.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):367-72 [16604543.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):180-5 [16634071.001]
  • [Cites] Acta Cytol. 1989 Mar-Apr;33(2):157-63 [2467480.001]
  • [Cites] Arch Pathol Lab Med. 1983 Oct;107(10):552-4 [6688519.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):889-93 [8249508.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1227-30 [8960033.001]
  • [Cites] Diagn Cytopathol. 1997 Feb;16(2):112-6 [9067100.001]
  • [Cites] Endoscopy. 1997 Nov;29(9):854-8 [9476770.001]
  • [Cites] Gastrointest Endosc. 1998 Feb;47(2):121-7 [9512275.001]
  • [Cites] Endoscopy. 1998 Aug;30 Suppl 1:A159-60 [9765114.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):341-8 [12789912.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):357-61 [10462656.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • (PMID = 17196112.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779360
  •  go-up   go-down


78. Daneshbod Y, Negahban S, Khademi B: Re: acinic cell carcinoma of salivary gland with massive deposits of globular amyloid. Int J Surg Pathol; 2009 Jun;17(3):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: acinic cell carcinoma of salivary gland with massive deposits of globular amyloid.
  • [MeSH-major] Amyloid / metabolism. Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321535.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid
  •  go-up   go-down


79. Garcia JJ, Al-Ahmadie HA, Gopalan A, Tickoo SK, Scardino PT, Reuter VE, Fine SW: Do prostatic transition zone tumors have a distinct morphology? Am J Surg Pathol; 2008 Nov;32(11):1709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do prostatic transition zone tumors have a distinct morphology?
  • Previous studies have proposed that the morphologic spectrum of prostatic glands of variable size with tall columnar cells displaying basally oriented nuclei and clear to pale pink cytoplasm (TZ-LOOK) is characteristic of the well to moderately differentiated component of transition zone (TZ) tumors.
  • In a recent report, we identified dominant peripheral zone (PZ) and TZ tumors situated anterior to the prostatic urethra.
  • Currently, we evaluate the histopathologic features of 215 dominant tumors, including 63 TZ and 73 anterior PZ lesions and an additional cohort of 79 posterior PZ tumors, in radical prostatectomy specimens, to identify the prevalence of this morphology in tumors of different zonal origin.
  • Each dominant tumor was assigned a TZ-LOOK extent score of 0 to 4, with 0 = no such morphology, 1 = 1% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = >75%.
  • Overall, 121/215 (56%) tumors showed some degree of this histology, including 56 of 63 (89%) TZ tumors and 65 of 152 (43%) PZ tumors (P<0.0001).
  • However, only 31/63 (49%) TZ tumors had >50% TZ-LOOK.
  • Among PZ tumors, 6/152 (4%) had predominant (>50%) TZ-LOOK morphology, yet 23/152 (15%) of all PZ tumors and 23/65 (35%) of PZ tumors displaying any degree of TZ-LOOK had scores of 2 to 3 (>25%; nonfocal).
  • In tumors of both zones with predominant (scores 3 to 4; >50%) TZ-LOOK histology, darker glands of usual acinar adenocarcinoma was often seen at the periphery.
  • Conversely, in tumors with nonpredominant TZ-LOOK (scores 1 to 2; <or=50%), these glands were frequently admixed with small glands bearing dark cytoplasm.
  • In this series, we demonstrate that some degree of TZ-LOOK morphology is twice as frequent in dominant TZ tumors than in PZ tumors.
  • Tumors demonstrating >50% of this histology are very likely of TZ origin, but this scenario occurs in only half of TZ tumors.
  • Importantly, the TZ-LOOK is nonfocal in up to 35% of PZ tumors exhibiting any degree of this morphology.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem Suppl. 1994;19:267-9 [7823599.001]
  • [Cites] Urology. 2003 Apr;61(4):748-53 [12670559.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] J Urol. 1995 Nov;154(5):1795-7 [7563349.001]
  • [Cites] J Urol. 1996 Feb;155(2):605-6 [8558670.001]
  • [Cites] Urology. 1996 Nov;48(5):751-6 [8911519.001]
  • [Cites] J Urol. 1997 Jan;157(1):204-6 [8976251.001]
  • [Cites] J Urol. 1997 Feb;157(2):556-8 [8996355.001]
  • [Cites] J Urol. 1997 Nov;158(5):1886-90 [9334623.001]
  • [Cites] Int J Urol. 1997 Nov;4(6):567-71 [9477185.001]
  • [Cites] Urology. 1998 Jul;52(1):89-93 [9671876.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1239-46 [9777986.001]
  • [Cites] Eur Urol. 1999 Apr;35(4):294-7 [10087391.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1221-5 [15610093.001]
  • [Cites] J Urol. 2005 Mar;173(3):737-41 [15711259.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1189-93 [14501722.001]
  • [Cites] Radiology. 2003 Oct;229(1):241-7 [12920178.001]
  • [Cites] Pathology. 2003 Dec;35(6):467-71 [14660095.001]
  • [Cites] Invest Urol. 1978 Jan;15(4):340-5 [75197.001]
  • [Cites] Prostate. 1981;2(1):35-49 [7279811.001]
  • [Cites] J Urol. 1988 Jan;139(1):61-5 [3336108.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):897-906 [3202246.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] J Urol. 1991 Jul;146(1):78-83; discussion 83-4 [1711589.001]
  • [Cites] J Urol. 1991 Oct;146(4):1069-76 [1895423.001]
  • [Cites] Br J Urol. 1991 Nov;68(5):499-509 [1747726.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):258-66 [1555836.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] Cancer Invest. 1994;12(4):425-37 [8032966.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):863-70 [7520673.001]
  • [Cites] Urol Int. 2005;74(1):23-6 [15711104.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):916-21; discussion 921 [16126324.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1167-71 [17026586.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):430-5 [17412489.001]
  • [Cites] Adv Anat Pathol. 2007 Nov;14(6):401-7 [18049129.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):229-35 [18223325.001]
  • [Cites] J Urol. 2008 Apr;179(4):1335-8; discussion 1338-9 [18289601.001]
  • [Cites] J Urol. 2000 Jun;163(6):1751-5 [10799175.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1039-46 [10935644.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):441-6 [11331962.001]
  • [Cites] BJU Int. 2002 Jan;89(1):33-9 [11849157.001]
  • [Cites] Urology. 2001 Jun;57(6):1117-20 [11377321.001]
  • [Cites] BJU Int. 2002 Jun;89(9):886-9 [12010233.001]
  • [Cites] Semin Surg Oncol. 1995 Jan-Feb;11(1):9-22 [7754280.001]
  • (PMID = 18769336.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092629-10; United States / NCI NIH HHS / CA / P50 CA092629; United States / NCI NIH HHS / CA / P50 CA092629-10
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS237591; NLM/ PMC3010973
  •  go-up   go-down


80. Epstein JI: An update of the Gleason grading system. J Urol; 2010 Feb;183(2):433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The grading of variants and subtypes of acinar adenocarcinoma of the prostate, including cancer with vacuoles, foamy gland carcinoma, ductal adenocarcinoma, pseudohyperplastic carcinoma and small cell carcinoma have also been modified.
  • For needle biopsy with different cores showing different grades, the current recommendation is to report the grades of each core separately, whereby the highest grade tumor is selected as the grade of the entire case to determine treatment, regardless of the percent involvement.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20006878.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


81. Hyun O J, Yoo IeR, Jung CK, Hoon Kim S, Chung SK: F-18 FDG PET/CT findings of dedifferentiated acinic cell carcinoma. Clin Nucl Med; 2010 Jun;35(6):473-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET/CT findings of dedifferentiated acinic cell carcinoma.
  • [MeSH-major] Cell Dedifferentiation. Fluorodeoxyglucose F18. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479609.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Wargo JA, Warshaw AL: Surgical approach to pancreatic exocrine neoplasms. Minerva Chir; 2005 Dec;60(6):445-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review, we will explore the contemporary clinical management of pancreatic adenocarcinoma, acinar cell carcinoma, and cystic neoplasms of the pancreas.
  • The pathogenesis and epidemiology of these tumors will also be examined.
  • [MeSH-minor] Adenocarcinoma / surgery. Algorithms. Carcinoma, Acinar Cell / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma / surgery. Cystadenoma / surgery. Decision Trees. Humans. Magnetic Resonance Imaging. Neoadjuvant Therapy / methods. Neoplasm Staging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401999.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 181
  •  go-up   go-down


83. Sygut D, Bień S, Ziółkowska M, Sporny S: Immunohistochemical expression of androgen receptor in salivary gland cancers. Pol J Pathol; 2008;59(4):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accidental discovery of androgen receptor (AR) expression in high-grade salivary gland cancer led to evaluation of that finding.
  • In this study we evaluated the immunohistochemical expression of AR in a series of 37 formalin-fixed, paraffin-embedded malignant salivary gland tumors using two commercially available antibodies.
  • Nuclear immunoreactivity for AR was demonstrated in 3 of 4 salivary duct carcinomas, 2 of 7 adenocarcinomas NOS and 1 of 2 carcinoma ex pleomorphic adenoma for both antibodies.
  • There was no immunoreactivity seen in 13 adenoid cystic carcinomas, 7 mucoepidermoid carcinomas and 4 acinic cell carcinomas.
  • [MeSH-major] Carcinoma / metabolism. Receptors, Androgen / biosynthesis. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391487.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


84. Mizuno Y, Sumi Y, Nachi S, Ito Y, Marui T, Saji S, Matsutomo H: Acinar cell carcinoma arising from an ectopic pancreas. Surg Today; 2007;37(8):704-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma arising from an ectopic pancreas.
  • We herein report a rare case of ectopic pancreatic acinar cell carcinoma (ACC) which presented as a submucosal tumor of the pylorus.
  • Esophago-gastroduodenal endoscopy showed no mucosal lesions, but a submucosal tumor was observed around the pylorus.
  • We diagnosed a gastrointestinal stromal tumor or malignant lymphoma preoperatively, and decided to perform an operation in order to confirm the diagnosis and select the optimal treatment.
  • The resected specimen showed the 7.6 x 4.9-cm size tumor to mainly originate from the pylorus.
  • Histopathologically, the tumor was identified as pancreatic ACC with lymph node metastasis.
  • The tumor cells were labeled by immunohistochemical staining for alpha1-antitrypsin.
  • Because of the tumor location, we considered the tumor to have originated from the ectopic pancreatic tissue in the stomach.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology. Pylorus / pathology. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):276-9 [15368114.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] J Surg Oncol. 2004 Jul 15;87(1):53-7 [15221920.001]
  • [Cites] Minerva Gastroenterol Dietol. 1994 Sep;40(3):101-3 [7948318.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1671-4 [16033080.001]
  • [Cites] Pancreas. 2001 Jul;23(1):109-12 [11451140.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • (PMID = 17643220.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Khalili M, Wax BN, Reed WP, Schuss A, Drexler S, Weston SR, Katz DS: Radiology-pathology conference. Acinar cell carcinoma of the pancreas. Clin Imaging; 2006 Sep-Oct;30(5):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology-pathology conference. Acinar cell carcinoma of the pancreas.
  • Acinar cell carcinoma (ACC) is a rare tumor that constitutes 1% of pancreatic neoplasms.
  • ACC is defined as a carcinoma exhibiting pancreatic enzyme production by neoplastic cells.
  • In this Radiology-Pathology Conference, the clinical presentation and imaging findings of a patient with ACC of the pancreas, along with the differential diagnosis, are reviewed.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Intestinal Obstruction / diagnosis. Pancreatic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919557.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Stelow EB, Bardales RH, Shami VM, Woon C, Presley A, Mallery S, Lai R, Stanley MW: Cytology of pancreatic acinar cell carcinoma. Diagn Cytopathol; 2006 May;34(5):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of pancreatic acinar cell carcinoma.
  • Acinar cell carcinoma (ACC) of the pancreas is extremely uncommon and its cytologic features have rarely been described.
  • We describe the cytologic features of cases we have seen, review the literature regarding its cytologic features and discuss the pitfalls that may be encountered and the use of immunohistochemistry for its diagnosis.
  • Original cytologic diagnoses included "acinar cell carcinoma," "pancreatic endocrine tumor," "favor neuroendocrine tumor, low-grade" and "non-diagnostic specimen."
  • The cytologic features included small to moderate-sized loose groups with numerous single cells, prominent acinar formation, little anisonucleosis and prominent nucleoli.
  • The cytologic features showed significant overlap with those of pancreatic endocrine tumors.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Female. Humans. Keratins / analysis. Liver Neoplasms / chemistry. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged. Pancreas / chemistry. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604543.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


87. Yaskiv O, Cao D, Humphrey PA: Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol; 2010 Apr;34(4):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns.
  • Cystic change in adenocarcinoma of the prostate is unusual and may be confused with benign cystic atrophy.
  • Limited data exist on the pathologic attributes of microcystic change in malignant prostatic glands.
  • The aim of this study was to assess histologic and immunohistologic characteristics of microcystic adenocarcinoma of the prostate.
  • This alteration was defined as cystic dilatation and rounded expansion of the malignant gland profile, with a flat luminal cell lining layer.
  • The greatest diameter of the dilated cancer glands was 0.4 to 0.9 mm, with a mean diameter 10-fold greater than adjacent small malignant glands.
  • The microcystic glands were typically adjacent to usual small acinar adenocarcinoma.
  • Atrophic features were seen at least focally in all cases, although many microcystic adenocarcinoma epithelia exhibited a moderate amount of cytoplasm.
  • Gleason grade 3 was the predominant grade of the adjacent nonmicrocystic malignant glands.
  • Ninety-six percent of the microcystic cases showed alpha-methylacyl CoA racemase overexpression and all cases showed complete basal cell loss (using 34betaE12 and p63 antibodies) in immunohistochemistry.
  • Microcystic adenocarcinoma of the prostate is a distinctive histomorphologic presentation of prostatic adenocarcinoma that is deceptively benign-looking at low magnifications.
  • Detection of intraluminal crystalloids or wispy blue mucin at low magnification, immunostains for alpha-methylacyl CoA racemase, and basal cells, and a search for adjacent usual small acinar adenocarcinoma are helpful diagnostic aids.
  • Diagnostic awareness of this growth pattern of prostatic carcinoma is important to avoid underdiagnosis of adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Atrophy. Biomarkers, Tumor / metabolism. Cysts / enzymology. Cysts / pathology. Humans. Male. Prostatectomy. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216381.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


88. Carrillo JF, Vázquez R, Ramírez-Ortega MC, Cano A, Ochoa-Carrillo FJ, Oñate-Ocaña LF: Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer; 2007 May 15;109(10):2043-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland.
  • BACKGROUND: Parotid gland carcinoma is an infrequent tumor, and series that report on these neoplasms are relatively scarce in the literature.
  • The objective of the current study was to identify prognostic factors in patients with parotid gland carcinoma and to develop a method for defining the probability of recurrence.
  • METHODS: Patients with parotid gland carcinoma who were treated at the authors' institution from January 1981 through December 2004 and who completed treatment constituted the study group.
  • Disease-free survival was calculated by using the Kaplan-Meier method.
  • Mucoepidermoid carcinoma was diagnosed in 34.6% of patients, adenoid cystic was diagnosed in 15.7% of patients, adenocarcinoma was diagnosed in 14.3% of patients, and acinic cell carcinoma was diagnosed in 9.4% of patients.
  • The median disease-free survival was 8.3 years (95% confidence interval [95% CI], 4.3-12.2 years).
  • Logistic regression analysis confirmed tumor classification, facial nerve palsy, grade of tumor differentiation, patient age, and surgical margins as recurrence-associated factors (P < .00001).
  • The 5-year disease-free survival rates for these groups were 18.7%, 53.9%, and 99.9%, respectively (P = .00001).
  • [MeSH-major] Carcinoma / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Logistic Models. Male. Middle Aged. Models, Statistical. Parotid Gland / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 17410532.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Lee JH, Lee JH, Kim A, Kim I, Chae YS: Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas. Pathol Int; 2005 Jul;55(7):386-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas.
  • The differential diagnosis of salivary gland carcinoma is often difficult because of the confusing histopathological features of the different types of salivary gland carcinomas.
  • The expression of MUC3, MUC5AC, MUC6, cytokeratin (CK)7 and CK20 was studied in 20 mucoepidermoid carcinomas (MEC), 20 adenoid cystic carcinomas (AdCC), and 11 acinic cell carcinomas (ACC).
  • These findings will be very useful for the differential diagnosis of the salivary gland carcinomas.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Keratin-20. Keratin-7. Keratins / biosynthesis. Male. Middle Aged. Mucin 5AC. Mucin-3. Mucins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982212.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-3; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


90. Hosoda W, Takagi T, Mizuno N, Shimizu Y, Sano T, Yamao K, Yatabe Y: Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int; 2010 May;60(5):358-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration.
  • Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has enabled clinicians to histologically diagnose pancreatic tumors.
  • Using immunostaining of CK7, CDX2, neuroendocrine markers and KRAS mutation analysis, we examined 57 FNA cell block sections and 61 surgically-resected specimens (25 invasive ductal carcinomas, 25 endocrine tumors, and 11 acinar cell tumors).
  • In the majority of the matched pairs, the diagnoses between EUS-FNA and surgical specimens were concordant using the following criteria: neuroendocrine markers negative, CK7 positive, and mutated KRAS gene for invasive ductal carcinomas; neuroendocrine markers diffusely positive, CK7 and CDX2 negative, and wild-type KRAS gene for well-differentiated endocrine tumors; and neuroendocrine markers no more than focal positive, CK7 and CDX2 with various staining patterns, and wild-type KRAS gene for acinar cell carcinomas.
  • Expression of CK7 and/or CDX2 in addition to KRAS mutations were occasionally seen in endocrine carcinomas, but not in well-differentiated endocrine tumors, suggesting that ductal differentiation in an endocrine tumor may be a predictor of aggressive disease.
  • The usefulness of these markers was confirmed using 13 additional pancreatic tumors, prospectively.
  • Although minimal in selection, these markers are helpful in making diagnosis from EUS-FNA specimens of the major pancreatic tumors.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Islet Cell / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Endosonography / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. DNA Mutational Analysis. DNA, Neoplasm / analysis. Homeodomain Proteins / metabolism. Humans. Keratin-7 / metabolism. Pancreas / metabolism. Pancreas / pathology. Pancreatectomy. Prognosis. Prospective Studies. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. ras Proteins / genetics. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518885.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / KRAS protein, human; 0 / Keratin-7; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


91. Du LX, Yuan JP, Guan H, Zhang WD, Liang BL: [Magnetic resonance imaging for diagnosis of parotid malignant tumors and the pathological basis]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):1107-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging for diagnosis of parotid malignant tumors and the pathological basis].
  • OBJECTIVE: To investigate magnetic resonance imaging (MRI) features of parotid malignant tumors and study their pathological basis.
  • METHODS: Forty-seven patients with parotid malignant tumors confirmed by surgery (41 patients) or biopsy (6 patients) were enrolled in this study.
  • Each of the MRI features was analyzed retrospectively and the typical MRI findings of common parotid malignant tumors were summarized.
  • RESULTS: MRI allowed accurate diagnosis of parotid malignant tumors.
  • Four patients with low-grade mucoepidermoid carcinoma showed well-defined tumor margin and were difficult to distinguish from benign tumors.
  • Six patients with high-grade mucoepidermoid carcinoma had obscure margin of the tumor which easily underwent necrosis with liable lymph node involvement.
  • The 8 cases of adenoid cystic carcinoma was characterized by extensive invasion surrounding the parotid gland.
  • Most of 8 cases of malignant pleomorphic adenoma still showed high and heterogeneous signal on T2WI, with irregular shape and poorly defined margin.
  • The 4 cases of acinic cell carcinoma showed either regular or irregular tumor morphology, presenting with high signal intensity on T1WI and T(2)WI.
  • CONCLUSION: MRI is an important modality for the diagnosis of parotid malignant tumors.
  • Most of the common parotid malignant tumors have characteristic MRI and pathological features, which make possible their differential diagnosis.
  • [MeSH-major] Magnetic Resonance Imaging. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / pathology. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501408.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Johnykutty S, Miller CH, Hoda RS, Giampoli EJ: Fine-needle aspiration of dedifferentiated acinic cell carcinoma: Report of a case with cyto-histological correlation. Diagn Cytopathol; 2009 Oct;37(10):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of dedifferentiated acinic cell carcinoma: Report of a case with cyto-histological correlation.
  • Dedifferentiated Acinic Cell Carcinoma (DAcCC) is a rare salivary gland malignancy.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Cell Differentiation. Female. Humans. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19526576.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Neto AG, Pineda-Daboin K, Spencer ML, Luna MA: Sinonasal acinic cell carcinoma: a clinicopathologic study of four cases. Head Neck; 2005 Jul;27(7):603-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal acinic cell carcinoma: a clinicopathologic study of four cases.
  • BACKGROUND: Acinic cell carcinoma is a low-grade malignant epithelial salivary gland neoplasm with a predilection for the parotid gland.
  • To date, only 11 cases of sinonasal acinic cell carcinomas have been reported in the English-language literature.
  • We present the clinicopathologic features of four sinonasal acinic cell carcinomas.
  • METHODS: The demographic data and pathologic material of four patients with sinonasal acinic cell carcinoma identified from the files of the Department of Pathology at The University of Texas M. D.
  • Histologically, all tumors were composed of round to ovoid cells with clear and/or basophilic granular cytoplasm and round, hyperchromatic, small, eccentrically located nuclei.
  • CONCLUSIONS: Sinonasal acinic cell carcinoma is a distinct low-grade carcinoma that can be distinguished from other neoplasms by light microscopy and histochemical staining methods.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Nose Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900565.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


94. Reis-Filho JS, Natrajan R, Vatcheva R, Lambros MB, Marchió C, Mahler-Araújo B, Paish C, Hodi Z, Eusebi V, Ellis IO: Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. Histopathology; 2008 Jun;52(7):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.
  • AIMS: Acinic cell carcinomas (ACCs) and secretory carcinomas (SCs) of the breast are rare, low-grade malignancies that preferentially affect young female patients.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Acinar Cell / genetics. Gene Rearrangement. In Situ Hybridization, Fluorescence. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462362.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


95. Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N: Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol; 2005 Aug;41(7):716-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors.
  • We examined the expression of Centromere protein F (CENP-F) mRNA in 26 human salivary gland tumors (seven pleomorphic adenomas, three Warthin tumors, seven mucoepidermoid carcinomas, four adenoid cystic carcinomas, four acinic cell carcinomas and one malignant myoepithelioma) and four normal submandibular glands using the real time quantitative reverse transcription-polymerase chain reaction (RT-PCR).
  • The mean expression level of CENP-F mRNA was higher in malignant tumors (1.05+/-0.32) than normal submandibular glands (0.11+/-0.05) and benign tumors (0.46+/-0.16).
  • We found a significant association between the level of CENP-F mRNA expression and clinical stage in 16 malignant tumors (Mann-Whitney U test, p=0.027).
  • We also found a significant correlation between the Ki-67 labeling index and CENP-F expression in malignant tumors (Spearmans correlation coefficient by rank test, p=0.029).
  • These results indicate that human CENP-F mRNA is closely linked to the increased or abnormal cell proliferation in malignant conditions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Male. Microfilament Proteins. Middle Aged. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Submandibular Gland / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927522.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / centromere protein F
  •  go-up   go-down


96. Uzaslan E, Stuempel T, Ebsen M, Freudenberg N, Nakamura S, Costabel U, Guzman J: Surfactant protein A detection in primary pulmonary adenocarcinoma without bronchioloalveolar pattern. Respiration; 2005 May-Jun;72(3):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactant protein A detection in primary pulmonary adenocarcinoma without bronchioloalveolar pattern.
  • BACKGROUND: Immunohistochemical studies in human lung carcinoma reported positive staining of tumor cells for surfactant protein A (SP-A), especially in peripheral airway cell carcinoma, which include bronchioloalveolar carcinoma and in some reports also papillary subtypes.
  • OBJECTIVE: The purpose of this study was to determine the SP-A expression in tumor cells of lung adenocarcinoma without a bronchioloalveolar pattern, classified according to the WHO.
  • METHODS: In total, 169 primary adenocarcinomas of the lung (109 acinar, 32 solid with mucin, 24 papillary and 4 mucinous) were examined by immunohistochemistry for SP-A expression.
  • RESULTS: Twenty-five percent of acinar, 38% of papillary and 3% of solid adenocarcinoma with mucin showed a positive intracytoplasmic SP-A reaction of the tumor cells.
  • None of the mucinous adenocarcinomas stained for SP-A.
  • This study included the largest number of acinar adenocarcinomas and solid adenocarcinomas with mucin studied for SP-A.
  • We clearly demonstrated that also primary lung adenocarcinoma without a bronchioloalveolar pattern can express SP-A.
  • A positive staining of hyperplastic type II cells surrounding the tumors or entrapped in the tumor could clearly be differentiated from the SP-A-positive stain of tumor cells.
  • CONCLUSION: These results support the theory that SP-A-producing cells may generate not only bronchioloalveolar and papillary carcinoma, but also other subtypes of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Lung Neoplasms / metabolism. Pulmonary Surfactant-Associated Protein A / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 15942293.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pulmonary Surfactant-Associated Protein A
  •  go-up   go-down


97. Chuah KL, Yap WM, Tan HW, Koong HN: Recurrence of pulmonary acinic cell carcinoma. Arch Pathol Lab Med; 2006 Jul;130(7):932-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of pulmonary acinic cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Pathol Lab Med. 2003 Apr;127(4):e216-9 [12683906.001]
  • (PMID = 16831044.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


98. Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F, Sarkar FH: Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice. J Carcinog; 2006 Jul 05;5:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female MT-tgf alpha mice of the MT100 line developed pancreatic proliferation, acinar-ductal metaplasia, multilocular cystic neoplasms, ductal adenocarcinomas and prominent fibrosis, while the lesions in males were less severe.
  • Ela-myc transgenic mice with a mixed C57BL/6, SJL and FVB genetic background developed pancreatic tumors at 2-7 months of age, and half of the tumors were ductal adenocarcinomas, similar to what was reported originally by Sandgren et al 1.
  • However, in 20% of the mice, the tumors metastasized to the liver.
  • MT100/Ela-myc and MT-tgf alpha-ES/Ela-myc double transgenic mice developed not only acinar carcinomas and mixed carcinomas as previously reported but also various ductal-originated lesions, including multilocular cystic neoplasms and ductal adenocarcinomas.
  • The double transgenic tumors were more malignant and metastasized to the liver at a higher frequency (33%) compared with the Ela-myc tumors.
  • Sequencing of the coding region of p16ink4, k-ras and Rb cDNA in small numbers of pancreatic tumors did not identify mutations.
  • The short latency for tumor development, the variety of tumor morphology and the liver metastases seen in Ela-myc and MT-tgf alpha/Ela-myc mice make these animals good models for investigating new therapeutic and preventive strategies for pancreatic cancer.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):635-43 [11756558.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):802-8 [11533659.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1403-4 [12045253.001]
  • [Cites] Pancreatology. 2001;1(4):363-8 [12120215.001]
  • [Cites] Pancreatology. 2002;2(5):440-8 [12378111.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):353-8 [12378529.001]
  • [Cites] Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275 [12399802.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:13 [12636873.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(1):43-60 [12909737.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(1):71-8 [12909739.001]
  • [Cites] Biochem J. 1992 Nov 1;287 ( Pt 3):681-4 [1445231.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Lab Invest. 2003 Oct;83(10):1437-49 [14563945.001]
  • [Cites] J Okla State Med Assoc. 2003 Oct;96(10):485-94 [14619604.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3127-38 [14681205.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):7-11 [14749121.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1612-9 [15083194.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):238-44 [15231857.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1129-39 [15466380.001]
  • [Cites] Methods Mol Med. 2005;103:1-13 [15542896.001]
  • [Cites] Methods Mol Med. 2005;103:217-43 [15542910.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6075-86 [16115953.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):171-2 [16169459.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] J Pathol. 1991 Feb;163(2):111-6 [1707959.001]
  • [Cites] Pancreas. 1991 Mar;6(2):150-6 [1886883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):93-7 [1986386.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Mol Carcinog. 1990;3(6):379-86 [2278633.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1137-46 [2350785.001]
  • [Cites] Science. 1987 Oct 9;238(4824):188-93 [2821617.001]
  • [Cites] Histopathology. 1985 Aug;9(8):841-56 [2997015.001]
  • [Cites] Cell. 1987 Mar 27;48(6):1023-34 [3470144.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2075-82 [7554057.001]
  • [Cites] Gastroenterology. 1995 Feb;108(2):564-80 [7835600.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):696-701 [8080049.001]
  • [Cites] Biochem J. 1993 Dec 15;296 ( Pt 3):837-42 [8280083.001]
  • [Cites] Mol Cell Biol. 1993 Jan;13(1):320-30 [8417334.001]
  • [Cites] Carcinogenesis. 1996 Apr;17(4):779-85 [8625491.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:219-30 [10415867.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1307-17 [10713672.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G501-6 [10762602.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):143-64 [11021963.001]
  • [Cites] Swiss Surg. 2000;6(5):231-4 [11077487.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):568-74 [11180888.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):575-9 [11180889.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):550-5 [11212248.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):462-9 [11950922.001]
  • (PMID = 16822304.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100864
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC1559682
  •  go-up   go-down


99. Jung YH, Hah JH, Sung MW, Kim KH: Parotidotomy approach for a midcheek mass: a new surgical strategy. Laryngoscope; 2010 Mar;120(3):495-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The parotidotomy approach was accomplished in two cases with a malignant tumor (one acinic cell carcinoma, one low-grade mucoepidermoid carcinoma), four with a benign tumor (two pleomorphic adenoma, one basal cell adenoma, one facial nerve schwannoma), and in one case with a chronic inflammatory lesion (chronic sialadenitis).
  • For the two malignant tumors, there was no evidence of recurrence or metastasis at 2-year and 2.5-year follow-ups.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058313.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Michail P, Karavokyros I, Pikoulis E, Arvelakis A, Charminis G, Michail O, Theodoros D: Acinic cell carcinoma of the parotid gland in children: a case report and literature review. West Indian Med J; 2008 Jan;57(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the parotid gland in children: a case report and literature review.
  • Parotid acinic cell carcinoma is a rare malignancy in childhood.
  • Tumour resection revealed acinic cell carcinoma of the parotid gland.
  • The patient has been disease-free for the last five years.
  • We review the literature on acinic cell carcinomas of parotid glands in childhood.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565943.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Jamaica
  • [Number-of-references] 26
  •  go-up   go-down






Advertisement